@article{209d19fc7d704531b5164ac2d58b8582,
title = "Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study",
abstract = "Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. Results Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71{\^a}€ 0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76{\^a}€ 0.98], P =.027) and AD (Aβ1-42: HR = 0.79 [0.69{\^a}€ 0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72{\^a}€ 0.96], P =.012). Conclusion Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.",
keywords = "Alzheimer's disease, Aβ peptides, Epidemiology, Framingham, Heart, Incident, Incident dementia, Meta-analysis, Plasma biomarker, Study",
author = "Vincent Chouraki and Alexa Beiser and Linda Younkin and Preis, {Sarah Rosner} and Galit Weinstein and Oskar Hansson and Ingmar Skoog and Lambert, {Jean Charles} and Rhoda Au and Lenore Launer and Wolf, {Philip A.} and Steven Younkin and Sudha Seshadri",
note = "Funding Information: Three-City Study: The Three-City (3C) Study was performed as part of a collaboration among the Institut National de la Sant{\'e} et de la Recherche M{\'e}dicale (INSERM), the Victor Segalen-Bordeaux II University, and Sanofi-Synthelabo. The Fondation pour la Recherche M{\'e}dicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salari{\'e}s , Direction G{\'e}n{\'e}rale de la Sant{\'e} , MGEN , Institut de la Longevit{\'e} , Agence Francaise de Securit{\'e} Sanitaire des Produits de Sant{\'e} , the Aquitaine and Bourgogne Regional Councils , Fondation de France , and the joint French Ministry of Research / National Institute of Health and Medical Research “Cohortes et collections de donn{\'e}es biologiques” program. Lille G{\'e}nopole received an unconditional grant from Eisai . This work was additionally funded by the CNRS , the Nord Pas-de-Calais Regional Council , and the European Regional Development Fund , and grants from INSERM-DHOS-INCA (Project A08037ECS) and the European Community's cNEUPRO programme (contract LSHM-CT-2007-037950). Funding Information: Honolulu Asia Aging Study: This work was supported by the National Institutes of Health (National Institute on Aging contract NO1-AG-4-2149, cooperative agreements 5U01AG017155-09 and 5U01AG019349-08, and the Intramural Research Program of the National Institutes of Health and with resources at the Veterans Affairs Pacific Islands Health Care System). Funding Information: This work was supported by the dedication of the Framingham Heart Study participants. Funding Information: Framingham Heart Study: This work received support from the National Heart, Lung and Blood Institute 's Framingham Heart Study (contract no. N01-HC-25195) and grants from the National Institute of Neurological Disorders and Stroke ( NS17950 ) and the National Institute on Aging ( AG08122 , AG16495 , and AG033193 ). Publisher Copyright: {\textcopyright} 2015 The Alzheimer's Association.",
year = "2015",
month = mar,
day = "1",
doi = "10.1016/j.jalz.2014.07.001",
language = "English (US)",
volume = "11",
pages = "249--257.e1",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",
}